Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
The University of Sydney · Children's Hospital at Westmead · +8 more institutions
Abstract
We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination.
We evaluated clinical phenotypes, annualised relapse rates (ARR) prior and on immunotherapy and Expanded Disability Status Scale (EDSS), in 218 demyelinating episodes from 33 paediatric and 26 adult patients.
Citation impact
- FWCI
- 34.51
- Percentile
- 100%
- References
- 43
Authors
15- SRSudarshini Ramanathan
The University of Sydney, Children's Hospital at Westmead, Westmead Hospital
- SSShekeeb S. Mohammad
The University of Sydney, Children's Hospital at Westmead
- ETEsther Tantsis
The University of Sydney, Children's Hospital at Westmead, Macquarie University
- TKTina K. Nguyen
The University of Sydney, Children's Hospital at Westmead
- VMVera Merheb
The University of Sydney, Children's Hospital at Westmead
Topics & keywords
- Medicine
- Acute disseminated encephalomyelitis
- Rituximab
- Prednisone
- Expanded Disability Status Scale
- Multiple sclerosis
- Myelin oligodendrocyte glycoprotein
- Internal medicine
- Good health and well-being